Baseline V-RESOLVE Score Guided Stent Implantation in Coronary Bifurcation Lesions

Sponsor
China National Center for Cardiovascular Diseases (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05503407
Collaborator
(none)
1,104
1
2
4.4
252.7

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate if baseline V-RESOLVE score-guided PCI is associated with significant reduction of side branch occlusion rate compared to angiography-guided PCI in patients with coronary bifurcation lesions.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Baseline V-RESOLVE score-guided PCI
  • Procedure: Angiography-guided PCI
N/A

Detailed Description

A number of 1104 patients scheduled for elective percutaneous coronary intervention (PCI) with native coronary bifurcation lesions suitable for stent implantation are included in the present study. This study will be conducted in two stages with 552 patients each. In the first stage, all patients receive angiography-guided PCI. In the second stage, all patients receive PCI under the guidance of baseline V-RESOLVE score.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1104 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Baseline V-RESOLVE Score Guided Stent Implantation in Coronary Bifurcation Lesions
Anticipated Study Start Date :
Aug 20, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Baseline V-RESOLVE score-guided PCI

Lesions with baseline V-RESOLVE <14 scores would undergo either jailed wire technique (diameter of side branch [SB]<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of SB≥2.5mm); Lesions with baseline V-RESOLVE ≥14 scores would undergo either jailed balloon technique (diameter of SB<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of SB≥2.5mm).

Procedure: Baseline V-RESOLVE score-guided PCI
Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken. Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard KBI whatever the situation is. Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken. Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting.

Placebo Comparator: Angiography-guided PCI

The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.

Procedure: Angiography-guided PCI
The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.

Outcome Measures

Primary Outcome Measures

  1. side branch occlusion after main vessel stenting [Immediately after the main vessel]

    The primary endpoint is side branch occlusion, which is defined as any decrease in TIMI flow grade or absence of flow in side branch after main vessel stent well opposed.

Secondary Outcome Measures

  1. The elevation of biomarkers of peri-procedural myocardial injury [Creatine Kinase-Myocardial Band (CK-MB) and Troponin I]. [48h after Percutaneous Coronary Intervention (PCI)]

    Peri-procedural Myocardial Infarction (MI) is defined as biomarkers elevation ≥10 × upper reference limit (URL) for CK-MB and/or ≥70 × URL for troponin.

  2. Major adverse cardiac events (MACE) [12-month follow-up]

    Including all cause death, all myocardial infarction (MI) and target vessel revascularization

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Clinical Inclusion Criteria:

  2. Subject must be male or nonpregnant female ≥18 years of age and ≤75 years of age;

  3. Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia;

  4. Subject is eligible for PCI;

  5. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed;

  6. Subject is willing to comply with all protocol-required follow-up evaluation.

  7. Angiographic Inclusion Criteria:

  8. Subjects have coronary bifurcation lesions requiring PCI with stent implantation according to clinical guidelines and/or the operator's judgement;

  9. Visually estimated reference vessel diameter (RVD) of target main vessel ≥2.5 mm and ≤4.0 mm;

  10. Visually estimated RVD of target side branch ≥ 2.0mm;

  11. Coronary anatomy is likely to allow delivery of a study device to the target lesion(s);

Exclusion Criteria:
  1. Clinical Exclusion Criteria:

  2. Subject has a known allergy to contrast (that cannot be adequately pre-medicated) and/or the trial stent system or protocol-required concomitant medications (e.g., stent alloy, stainless steel, sirolimus, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin);

  3. Planned surgery within 6 months after the index procedure;

  4. Subject has one of the following (as assessed prior to the index procedure):

  • Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months;

  • Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.);

  • Planned procedure that may cause non-compliance with the protocol or confound data interpretation;

  1. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions;

  2. Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint;

  3. Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure;

  4. Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure);

  5. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential);

  6. Subject with left ventricular ejection fraction < 35%;

  7. Subject has preoperative renal dysfunction: serum creatinine>2.0mg/dl (176.82umol/L).

  8. Angiographic Exclusion Criteria:

  9. Left main lesions;

  10. In case of acute myocardial infarction of which the culprit vessel located at the left anterior descending (LAD) artery, the bifurcation lesion (LAD/diagonal branch [RVD>2.5mm]) which is proximal to occluded LAD segment should be excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fuwai Hospital Beijing Beijing China 100037

Sponsors and Collaborators

  • China National Center for Cardiovascular Diseases

Investigators

  • Principal Investigator: Kefei Dou, MD, PhD, Fuwai Hospital and National Center for Cardiovascular Diseases

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CHD center 23th ward, Professor, China National Center for Cardiovascular Diseases
ClinicalTrials.gov Identifier:
NCT05503407
Other Study ID Numbers:
  • 2020-1361
First Posted:
Aug 16, 2022
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CHD center 23th ward, Professor, China National Center for Cardiovascular Diseases
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022